Patents by Inventor Alice Mead
Alice Mead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240033229Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: ApplicationFiled: February 16, 2023Publication date: February 1, 2024Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
-
Publication number: 20230032502Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy The disclosure further relates to the use of CBD in 5 combination with one or more anti-epileptic drugs (AEDs).Type: ApplicationFiled: March 28, 2022Publication date: February 2, 2023Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Orrin DEVINSKY
-
Publication number: 20200179303Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Orrin DEVINSKY
-
Publication number: 20200138738Abstract: The present invention relates in the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Surge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: ApplicationFiled: January 8, 2020Publication date: May 7, 2020Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
-
Patent number: 10603288Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: April 9, 2018Date of Patent: March 31, 2020Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 10583096Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: GrantFiled: March 28, 2017Date of Patent: March 10, 2020Assignee: GW RESEARCH LIMITEDInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Anne Comi
-
Publication number: 20200069608Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: ApplicationFiled: November 8, 2019Publication date: March 5, 2020Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Publication number: 20200000741Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: ApplicationFiled: September 13, 2019Publication date: January 2, 2020Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Publication number: 20190091171Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: ApplicationFiled: November 21, 2018Publication date: March 28, 2019Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Publication number: 20190083418Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: ApplicationFiled: March 28, 2017Publication date: March 21, 2019Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Anne Comi
-
Publication number: 20180338931Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: ApplicationFiled: April 9, 2018Publication date: November 29, 2018Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 10137095Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: November 27, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 10111840Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: October 13, 2015Date of Patent: October 30, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 10092525Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: October 9, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9956185Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: May 1, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9956183Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: May 1, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9956184Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: May 1, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9956186Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: May 1, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9949937Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: April 24, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9949936Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: October 4, 2016Date of Patent: April 24, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Charuta Joshi, Angus Wilfong